Futura Medical plc

LSE FUM.L

Futura Medical plc Price to Book Ratio (P/B) on January 14, 2025

Futura Medical plc Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Futura Medical plc 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Futura Medical plc 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Futura Medical plc average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

LSE: FUM.L

Futura Medical plc

CEO	Mr. James Henry Barder
IPO Date	July 22, 2003
Location	United Kingdom
Headquarters	Surrey Technology Centre
Employees	12
Sector	Health Care
Industries Pharmaceuticals

Description

Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

Key trends

Past 5 years